|
| 肾综合征出血热抗病毒治疗及疫苗研发进展 |
| Advances in antiviral treatment and vaccine development of hemorrhagic fever with renal syndrome |
| |
| DOI：10.3969/j.issn.1007-8134.2020.03.002 |
| 中文关键词: 肾综合征出血热 抗病毒 利巴韦林 汉坦病毒 疫苗 |
| 英文关键词: hemorrhagic fever with renal syndrome antivirus ribavirin hantavirus vaccine |
| 基金项目:“十三五”国家科技重大专项（2017ZX10204401）；陕西省自然科学基金一般面上项目（2018JM7103）；唐都医院科技创新发展基金面上项目（2016JCYJ001） |
|
| 摘要点击次数: 1440 |
| 全文下载次数: 579 |
| 中文摘要: |
| 肾综合征出血热（hemorrhagic fever with renal syndrome, HFRS）是由汉坦病毒感染引起的一种自然疫源性疾病，在世界范围内广泛流行，我国一直是流行高发区，患者占所有HFRS患者一半以上，其主要临床特征为发热、出血、低血压休克和肾脏损害，严重危害人类健康。尽管抗病毒治疗和疫苗免疫接种可以防治汉坦病毒感染，但目前尚无特效抗病毒药物。近年来，随着医学科技进步，汉坦病毒的抗病毒治疗和疫苗研发有了新的进展。本文基于近年体内外研究及临床试验结果，对HFRS抗病毒治疗和疫苗研发进展作一综述。 |
| 英文摘要: |
| Hemorrhagic fever with renal syndrome (HFRS) is a natural focus disease caused by hantavirus infection, which is widely prevalent in the world. Accounting for more than half of all HFRS patients, China has always been a high prevalence area of HFRS. The main clinical features of HFRS are fever, hemorrhage, hypotensive shock and renal impairment, which seriously threatens human health. Although antiviral treatment and vaccination can prevent and treat hantavirus infection, there are currently no specific antiviral drugs. In recent years, with the development of medical technology, new advances have been made in the development of antiviral treatment and vaccines for hantavirus. Given the results of in vitro and in vivo studies and clinical trials in recent years, this review provides a summary of the advances in antiviral treatment and vaccine development of HFRS. |
|
HTML
查看全文
下载PDF阅读器 |
| 关闭 |